Eythropoesis

Reading File
Searching Images

erythropoiesis stages red blood cell development bone marrow

This composite medical image includes bone marrow smears and clinical photographs documenting the progression of a systemic illness, likely Parvovirus B19 infection. Diagnostic Images (Aa, Ab): Bone marrow smears (400x magnification) demonstrate a transition from hyperplastic marrow with active erythropoiesis (Aa) to a significant decrease in erythroblast density and maturation inhibition (Ab). Image Ab prominently displays a phagocytic cell containing numerous vacuoles and cellular debris (black arrow), indicative of hemophagocytic syndrome. Clinical Photographs (Ba-Cb): Serial photographs show evolving cutaneous manifestations. Initial findings (Ba, Bb) demonstrate blue-purple ecchymosis and diffuse mottling on the limbs and trunk. Later stages (Ca, Cb) reveal progressive purple-red ecchymotic lesions associated with the development of large, strained bullae filled with serous fluid on an erythematous base. The images illustrate the clinical and pathological manifestations of acute aplastic crisis and hemophagocytic lymphohistiocytosis (HLH) within the context of hematologic and infectious disease.

This composite medical image includes bone marrow smears and clinical photographs documenting the progression of a systemic illness, likely Parvovirus B19 infection. Diagnostic Images (Aa, Ab): Bone marrow smears (400x magnification) demonstrate a transition from hyperplastic marrow with active erythropoiesis (Aa) to a significant decrease in erythroblast density and maturation inhibition (Ab). Image Ab prominently displays a phagocytic cell containing numerous vacuoles and cellular debris (black arrow), indicative of hemophagocytic syndrome. Clinical Photographs (Ba-Cb): Serial photographs show evolving cutaneous manifestations. Initial findings (Ba, Bb) demonstrate blue-purple ecchymosis and diffuse mottling on the limbs and trunk. Later stages (Ca, Cb) reveal progressive purple-red ecchymotic lesions associated with the development of large, strained bullae filled with serous fluid on an erythematous base. The images illustrate the clinical and pathological manifestations of acute aplastic crisis and hemophagocytic lymphohistiocytosis (HLH) within the context of hematologic and infectious disease.

A pathophysiology diagram illustrating the disease progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) and the subsequent impact on erythropoiesis. The visual follows a peak-like trajectory: the left side shows the progression from MGUS (clonal plasma cells) to MM (plasma cell expansion), characterized by a thickening M-protein band and increasingly ineffective erythropoiesis leading to anemia. At the peak, malignant multiple myeloma cells dominate the bone marrow environment alongside sparse red blood cells and erythroid precursors. The downward right slope depicts therapeutic intervention using immunomodulatory drugs (IMiDsR) and the engagement of novel erythroid recovery pathways involving EPO, EPOR, and RHEX. This phase represents MM in remission (Normal PC) and the clinical restoration of erythropoiesis, visualized by the return of mature red blood cells and normal erythroid precursor levels. Key components include plasma cells, monoclonal (M) paraprotein bands, and the sequential maturation stages of the erythroid lineage.

A pathophysiology diagram illustrating the disease progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) and the subsequent impact on erythropoiesis. The visual follows a peak-like trajectory: the left side shows the progression from MGUS (clonal plasma cells) to MM (plasma cell expansion), characterized by a thickening M-protein band and increasingly ineffective erythropoiesis leading to anemia. At the peak, malignant multiple myeloma cells dominate the bone marrow environment alongside sparse red blood cells and erythroid precursors. The downward right slope depicts therapeutic intervention using immunomodulatory drugs (IMiDsR) and the engagement of novel erythroid recovery pathways involving EPO, EPOR, and RHEX. This phase represents MM in remission (Normal PC) and the clinical restoration of erythropoiesis, visualized by the return of mature red blood cells and normal erythroid precursor levels. Key components include plasma cells, monoclonal (M) paraprotein bands, and the sequential maturation stages of the erythroid lineage.

This composite diagnostic image displays a comparison chart of hematological cells from non-cancerous bone marrow aspirations, organized to show the maturation stages of the myeloid series. The visual consists of a grid with six columns, each representing a specific stage of development: Myeloblast (MB), Promyelocyte (PM), Myelocyte (M), Metamyelocyte (MM), Band (B), and Neutrophil (N). The cells are stained with Giemsa, revealing characteristic morphological changes in nuclear and cytoplasmic structure. Early stages (MB, PM) show large, round to oval nuclei with high nuclear-to-cytoplasmic (N:C) ratios and basophilic cytoplasm. As maturation progresses through the Myelocyte and Metamyelocyte stages, the nuclei become smaller and more indented. The Band (B) stage is characterized by an elongated, curved, non-segmented nucleus. The terminal stage, the Neutrophil (N), demonstrates distinct nuclear lobulation (typically 2-3 lobes) and increased cytoplasmic granularity. This image serves as an educational reference for identifying white blood cell precursors in the context of healthy hematopoiesis and chronic myelogenous leukemia (CML) classification.

This composite diagnostic image displays a comparison chart of hematological cells from non-cancerous bone marrow aspirations, organized to show the maturation stages of the myeloid series. The visual consists of a grid with six columns, each representing a specific stage of development: Myeloblast (MB), Promyelocyte (PM), Myelocyte (M), Metamyelocyte (MM), Band (B), and Neutrophil (N). The cells are stained with Giemsa, revealing characteristic morphological changes in nuclear and cytoplasmic structure. Early stages (MB, PM) show large, round to oval nuclei with high nuclear-to-cytoplasmic (N:C) ratios and basophilic cytoplasm. As maturation progresses through the Myelocyte and Metamyelocyte stages, the nuclei become smaller and more indented. The Band (B) stage is characterized by an elongated, curved, non-segmented nucleus. The terminal stage, the Neutrophil (N), demonstrates distinct nuclear lobulation (typically 2-3 lobes) and increased cytoplasmic granularity. This image serves as an educational reference for identifying white blood cell precursors in the context of healthy hematopoiesis and chronic myelogenous leukemia (CML) classification.

A pathophysiology diagram illustrating the stages of T-cell development and differentiation across anatomical compartments. The flow begins in the Bone Marrow with Hematopoietic Stem Cells (HSC) and Common Lymphoid Precursors (CLP), which migrate through the Blood to the Thymus. Within the thymus, the diagram details successive developmental stages: T-cell precursor, Pro-T cell (Double Negative, DN), Pre-T cell (DN), and Immature T cells (Double Positive, DP). Key molecular events are labeled, including TCR β-chain and α-chain rearrangements, pre-TCR formation, and positive/negative selection. The cells transition from DP to Mature T cells (Single Positive, SP), categorized as either CD8+ or CD4+. Following a second migration through the Blood to Peripheral Tissues, the Naive CD4+ T cell undergoes terminal differentiation. The diagram maps the cytokine-driven pathways (including IL-12, IFN-γ, IL-4, TGF-β, IL-6, IL-1β, IL-23, and TNF-α) that lead to specific T-helper (Th) cell subsets: Th1, Th2, Th3, Th9, Th17, and Th22. The visual uses color-coded spheres to represent maturing cells and directional arrows to denote cellular migration and lineage progression.

A pathophysiology diagram illustrating the stages of T-cell development and differentiation across anatomical compartments. The flow begins in the Bone Marrow with Hematopoietic Stem Cells (HSC) and Common Lymphoid Precursors (CLP), which migrate through the Blood to the Thymus. Within the thymus, the diagram details successive developmental stages: T-cell precursor, Pro-T cell (Double Negative, DN), Pre-T cell (DN), and Immature T cells (Double Positive, DP). Key molecular events are labeled, including TCR β-chain and α-chain rearrangements, pre-TCR formation, and positive/negative selection. The cells transition from DP to Mature T cells (Single Positive, SP), categorized as either CD8+ or CD4+. Following a second migration through the Blood to Peripheral Tissues, the Naive CD4+ T cell undergoes terminal differentiation. The diagram maps the cytokine-driven pathways (including IL-12, IFN-γ, IL-4, TGF-β, IL-6, IL-1β, IL-23, and TNF-α) that lead to specific T-helper (Th) cell subsets: Th1, Th2, Th3, Th9, Th17, and Th22. The visual uses color-coded spheres to represent maturing cells and directional arrows to denote cellular migration and lineage progression.

A pathophysiology diagram illustrating the role of the transcription factor LRF/ZBTB7A in human hematopoiesis, specifically in erythroid and lymphoid development. The diagram shows the differentiation of Hematopoietic Stem Cells (HSCs) into three main lineages. 1) Erythroid Development: Occurring in the bone marrow, the pathway progresses from CMP to BFU-E, CFU-E, and through erythroid precursors (ProE, BasoE, PolyE, OrthoE) to mature RBCs. LRF/ZBTB7A is shown regulating the terminal stages of erythropoiesis. 2) B-cell Development: Traces maturation from CLP through Pro-B, Pre-B, and Immature B cells in the bone marrow, continuing to Mature B cells in secondary lymphoid organs, where LRF/ZBTB7A facilitates differentiation into Follicular B cells (FOB) and Germinal Center B cells (GCB). 3) T-cell Development: Located in the thymus, it shows transitions from DN T-cells to DP T-cells (CD4+/CD8+). LRF/ZBTB7A is associated with the lineage choice between CD8+ (Runx3) and CD4+ (Thpok) T-cells. The visual emphasizes nuclear condensation and cytoplasm changes during erythroid maturation.

A pathophysiology diagram illustrating the role of the transcription factor LRF/ZBTB7A in human hematopoiesis, specifically in erythroid and lymphoid development. The diagram shows the differentiation of Hematopoietic Stem Cells (HSCs) into three main lineages. 1) Erythroid Development: Occurring in the bone marrow, the pathway progresses from CMP to BFU-E, CFU-E, and through erythroid precursors (ProE, BasoE, PolyE, OrthoE) to mature RBCs. LRF/ZBTB7A is shown regulating the terminal stages of erythropoiesis. 2) B-cell Development: Traces maturation from CLP through Pro-B, Pre-B, and Immature B cells in the bone marrow, continuing to Mature B cells in secondary lymphoid organs, where LRF/ZBTB7A facilitates differentiation into Follicular B cells (FOB) and Germinal Center B cells (GCB). 3) T-cell Development: Located in the thymus, it shows transitions from DN T-cells to DP T-cells (CD4+/CD8+). LRF/ZBTB7A is associated with the lineage choice between CD8+ (Runx3) and CD4+ (Thpok) T-cells. The visual emphasizes nuclear condensation and cytoplasm changes during erythroid maturation.

This medical educational diagram illustrates the hematopoietic cell development pathways across three primary compartments: bone marrow, thymus, and spleen, specifically focusing on the expression of Notch receptors, ligands, and glycosyltransferases. In the Bone Marrow, the lineage progresses from Long-Term Hematopoietic Stem Cells (LT-HSC) through Multipotent Progenitors (MPP) to Common Myeloid Progenitors (CMP) and Common Lymphoid Progenitors (CLP), giving rise to various blood cells like megakaryocytes and erythrocytes. The Thymus section depicts T-cell maturation from Early Thymic Progenitors (ETP) through Double-Negative (DN1-4) and Double-Positive (DP) stages to CD4+ and CD8+ Single-Positive (SP) cells. The Spleen section details B-cell differentiation from transitional stages (T1, T2) to Follicular (Fo-B) and Marginal Zone (MZ-B) B cells. Throughout these pathways, the diagram maps the specific involvement of Notch1-4 receptors and ligands (Dll1, Dll3, Dll4, Jag1, Jag2), alongside key O-glycan glycosyltransferases like Pofut1, Lfng, Mfng, Rfng, and Eogt, highlighting their regulatory roles in lymphopoiesis and myelopoiesis.

This medical educational diagram illustrates the hematopoietic cell development pathways across three primary compartments: bone marrow, thymus, and spleen, specifically focusing on the expression of Notch receptors, ligands, and glycosyltransferases. In the Bone Marrow, the lineage progresses from Long-Term Hematopoietic Stem Cells (LT-HSC) through Multipotent Progenitors (MPP) to Common Myeloid Progenitors (CMP) and Common Lymphoid Progenitors (CLP), giving rise to various blood cells like megakaryocytes and erythrocytes. The Thymus section depicts T-cell maturation from Early Thymic Progenitors (ETP) through Double-Negative (DN1-4) and Double-Positive (DP) stages to CD4+ and CD8+ Single-Positive (SP) cells. The Spleen section details B-cell differentiation from transitional stages (T1, T2) to Follicular (Fo-B) and Marginal Zone (MZ-B) B cells. Throughout these pathways, the diagram maps the specific involvement of Notch1-4 receptors and ligands (Dll1, Dll3, Dll4, Jag1, Jag2), alongside key O-glycan glycosyltransferases like Pofut1, Lfng, Mfng, Rfng, and Eogt, highlighting their regulatory roles in lymphopoiesis and myelopoiesis.

Finding Sources
Searching Images

erythropoiesis EPO erythropoietin regulation stages proerythroblast reticulocyte

A pathophysiology diagram illustrating the molecular signaling pathway of Erythropoietin (EPO) in the context of vascular dementia (VD). The diagram is set against a stylized background of the brain, specifically the hippocampus. The pathway begins with EPO activating p-EPOR (phosphorylated erythropoietin receptor), which subsequently inhibits reactive oxygen species (ROS). The reduction in ROS leads to the activation of p-SHP2, which further triggers the phosphorylation of the BDNF/TrKB/PI3K/ERK1/2 axis. This signaling cascade results in downstream anti-apoptotic effects: an up-regulation of the anti-apoptotic protein Bcl-2 (indicated by a red upward arrow) and a down-regulation/inhibition of pro-apoptotic factors Bax, Caspase-3, and Caspase-9 (indicated by a red downward arrow). The final outcome of this mechanism is described as resisting apoptosis and improving cognitive dysfunction caused by chronic hypoperfusion. This visual resource is intended for educational purposes regarding neuroprotection and the therapeutic potential of EPO in neurodegenerative conditions.

A pathophysiology diagram illustrating the molecular signaling pathway of Erythropoietin (EPO) in the context of vascular dementia (VD). The diagram is set against a stylized background of the brain, specifically the hippocampus. The pathway begins with EPO activating p-EPOR (phosphorylated erythropoietin receptor), which subsequently inhibits reactive oxygen species (ROS). The reduction in ROS leads to the activation of p-SHP2, which further triggers the phosphorylation of the BDNF/TrKB/PI3K/ERK1/2 axis. This signaling cascade results in downstream anti-apoptotic effects: an up-regulation of the anti-apoptotic protein Bcl-2 (indicated by a red upward arrow) and a down-regulation/inhibition of pro-apoptotic factors Bax, Caspase-3, and Caspase-9 (indicated by a red downward arrow). The final outcome of this mechanism is described as resisting apoptosis and improving cognitive dysfunction caused by chronic hypoperfusion. This visual resource is intended for educational purposes regarding neuroprotection and the therapeutic potential of EPO in neurodegenerative conditions.

This composite educational graphic details the genetic regulation and spatial expression of the Erythropoietin Receptor (EPOR) gene during development. Panel A displays a genomic sequence alignment comparison between Human, Rhesus, Mouse, and Rat EPOR proximal promoter regions. It highlights conserved regulatory binding sites, including GATA-1, Sp1, and multiple E-box motifs, which are critical for erythroid and non-hematopoietic gene expression. Panels B and C present clinical laboratory photographs of transgenic mouse embryos using a beta-galactosidase reporter system (blue staining) to visualize EPOR promoter activity. Panel B shows expression in the developing embryonic brain at day E9.5. Panel C illustrates a broader expression pattern at embryonic days E12.5 and E13.5, with prominent staining in the visceral (branchial) arches, the bases of the developing forelimbs and hindlimbs, the intercostal rib regions (showing a characteristic striped pattern), and the fetal liver. This image demonstrates that while EPOR is vital for erythropoiesis, its expression is also localized in neural and musculoskeletal tissues during gestation.

This composite educational graphic details the genetic regulation and spatial expression of the Erythropoietin Receptor (EPOR) gene during development. Panel A displays a genomic sequence alignment comparison between Human, Rhesus, Mouse, and Rat EPOR proximal promoter regions. It highlights conserved regulatory binding sites, including GATA-1, Sp1, and multiple E-box motifs, which are critical for erythroid and non-hematopoietic gene expression. Panels B and C present clinical laboratory photographs of transgenic mouse embryos using a beta-galactosidase reporter system (blue staining) to visualize EPOR promoter activity. Panel B shows expression in the developing embryonic brain at day E9.5. Panel C illustrates a broader expression pattern at embryonic days E12.5 and E13.5, with prominent staining in the visceral (branchial) arches, the bases of the developing forelimbs and hindlimbs, the intercostal rib regions (showing a characteristic striped pattern), and the fetal liver. This image demonstrates that while EPOR is vital for erythropoiesis, its expression is also localized in neural and musculoskeletal tissues during gestation.

This diagnostic image illustrates the spatial and temporal expression patterns of Erythropoietin (EPO) and its receptor (EPOR) in the developing mammalian (rat) somatosensory cortex using in situ hybridization (ISH). The panels are divided into EPOR (A) and EPO (B) across three developmental stages: Embryonic day 16 (E16), E19, and Postnatal day 7 (P7). At E16, both transcripts show generalized expression, except in the marginal zone (MZ). By E19, a more differentiated laminar pattern emerges; EPOR and EPO labeling is concentrated in the ventricular zone (VZ), subventricular zone (SVZ), lower intermediate zone (IZ), and cortical plate (CP). At P7, coronal sections and high-magnification cortical columns demonstrate layer-specific distribution. EPOR is prominently expressed in the upper cortical layers and proximal to the ventricle, whereas EPO transcript peaks in deep layers (V-VI) and the periventricular area. These images highlight the regulatory role of EPO signaling during radial neuronal migration and the formation of the barrel cortex. Labels identify anatomical zones (MZ, CP, IZ, SVZ, VZ) and postnatal cortical layers (I-VI).

This diagnostic image illustrates the spatial and temporal expression patterns of Erythropoietin (EPO) and its receptor (EPOR) in the developing mammalian (rat) somatosensory cortex using in situ hybridization (ISH). The panels are divided into EPOR (A) and EPO (B) across three developmental stages: Embryonic day 16 (E16), E19, and Postnatal day 7 (P7). At E16, both transcripts show generalized expression, except in the marginal zone (MZ). By E19, a more differentiated laminar pattern emerges; EPOR and EPO labeling is concentrated in the ventricular zone (VZ), subventricular zone (SVZ), lower intermediate zone (IZ), and cortical plate (CP). At P7, coronal sections and high-magnification cortical columns demonstrate layer-specific distribution. EPOR is prominently expressed in the upper cortical layers and proximal to the ventricle, whereas EPO transcript peaks in deep layers (V-VI) and the periventricular area. These images highlight the regulatory role of EPO signaling during radial neuronal migration and the formation of the barrel cortex. Labels identify anatomical zones (MZ, CP, IZ, SVZ, VZ) and postnatal cortical layers (I-VI).

Educational panel illustrating the effect of Erythropoietin (EPO) on bone fracture healing at day 28 post-surgery in a femur model. (A) Radiological Comparison: Lateral X-rays of the femur showing a control (Con) group and an EPO-treated group. The EPO-treated femur demonstrates a more robust, radiopaque bony callus at the fracture site compared to the control. (B) Bar Graph: Quantitative X-ray scores indicating a significantly higher healing score for the EPO group (p < 0.01). (C) Micro-CT Analysis: 3D micro-computed tomography reconstructions of the new bone regenerates. The EPO images show increased bone bridging, greater spatial distribution of mineralized tissue, and a more complex trabecular network than the control. (D) Quantitative Histomorphometry: Three bar graphs showing significant increases (p < 0.05 or p < 0.01) in bone microstructure parameters for the EPO group, including bone volume (BV), bone volume/total volume (BV/TV), and bone surface (BS). The content demonstrates EPO's role as a pro-osteogenic factor in enhancing bone consolidation and mineral density during orthopedic repair.

Educational panel illustrating the effect of Erythropoietin (EPO) on bone fracture healing at day 28 post-surgery in a femur model. (A) Radiological Comparison: Lateral X-rays of the femur showing a control (Con) group and an EPO-treated group. The EPO-treated femur demonstrates a more robust, radiopaque bony callus at the fracture site compared to the control. (B) Bar Graph: Quantitative X-ray scores indicating a significantly higher healing score for the EPO group (p < 0.01). (C) Micro-CT Analysis: 3D micro-computed tomography reconstructions of the new bone regenerates. The EPO images show increased bone bridging, greater spatial distribution of mineralized tissue, and a more complex trabecular network than the control. (D) Quantitative Histomorphometry: Three bar graphs showing significant increases (p < 0.05 or p < 0.01) in bone microstructure parameters for the EPO group, including bone volume (BV), bone volume/total volume (BV/TV), and bone surface (BS). The content demonstrates EPO's role as a pro-osteogenic factor in enhancing bone consolidation and mineral density during orthopedic repair.

This pathophysiology diagram illustrates the regulatory signaling pathways governing the balance between erythroid precursor proliferation and differentiation. The visual is divided into two thematic sections: a peach-colored 'Proliferation' panel on the left and a light purple 'Differentiation' panel on the right. Centrally, GATA-1 acts as a master regulator. On the proliferation side, GATA-1 inhibits the expression of Kit, while the Exosome Complex positively influences Kit transcription, maintaining a 'Type 2 Coherent Feed-forward Loop' for self-renewal. On the differentiation side, GATA-1 promotes the expression of EpoR (Erythropoietin Receptor), which activates downstream signaling to drive erythroid maturation. The Exosome Complex is shown to inhibit differentiation and EpoR signaling; however, GATA-1 also represses the Exosome Complex subunits, thereby lifting this inhibition to facilitate maturation. This 'Type 4 Coherent Feed-forward Loop' orchestrates the developmental switch from SCF-induced Kit signaling to pro-differentiation Epo signaling during erythropoiesis.

This pathophysiology diagram illustrates the regulatory signaling pathways governing the balance between erythroid precursor proliferation and differentiation. The visual is divided into two thematic sections: a peach-colored 'Proliferation' panel on the left and a light purple 'Differentiation' panel on the right. Centrally, GATA-1 acts as a master regulator. On the proliferation side, GATA-1 inhibits the expression of Kit, while the Exosome Complex positively influences Kit transcription, maintaining a 'Type 2 Coherent Feed-forward Loop' for self-renewal. On the differentiation side, GATA-1 promotes the expression of EpoR (Erythropoietin Receptor), which activates downstream signaling to drive erythroid maturation. The Exosome Complex is shown to inhibit differentiation and EpoR signaling; however, GATA-1 also represses the Exosome Complex subunits, thereby lifting this inhibition to facilitate maturation. This 'Type 4 Coherent Feed-forward Loop' orchestrates the developmental switch from SCF-induced Kit signaling to pro-differentiation Epo signaling during erythropoiesis.

This composite educational image illustrates the hematopoietic and morphological effects of Stk40 knockout (KO) in mouse embryos. (a-d) Scatter and bar graphs display hematological indices: the KO group shows a significant reduction in hematocrit (HCT), red blood cell (RBC) count, and hemoglobin (Hb) concentration, while erythropoietin (Epo) levels are significantly elevated compared to wild-type (WT) and heterozygous (Het) controls. (e) Comparative clinical photographs of E14.5 embryos show that the Stk40 KO embryo exhibits severe subcutaneous edema (white arrowheads) and a diminished fetal liver shadow (black arrows) relative to the WT. (f) Macroscopic images of harvested fetal livers demonstrate marked hypoplasia in the KO liver compared to the WT. (g-j) Quantitative analysis and flow cytometry data show a decrease in total fetal liver cellularity and absolute numbers of Ter119+ erythroid cells in KO embryos, indicating impaired definitive erythropoiesis. Collectively, the data demonstrate that Stk40 deficiency leads to fetal anemia, edema, and hepatic hematopoietic defects.

This composite educational image illustrates the hematopoietic and morphological effects of Stk40 knockout (KO) in mouse embryos. (a-d) Scatter and bar graphs display hematological indices: the KO group shows a significant reduction in hematocrit (HCT), red blood cell (RBC) count, and hemoglobin (Hb) concentration, while erythropoietin (Epo) levels are significantly elevated compared to wild-type (WT) and heterozygous (Het) controls. (e) Comparative clinical photographs of E14.5 embryos show that the Stk40 KO embryo exhibits severe subcutaneous edema (white arrowheads) and a diminished fetal liver shadow (black arrows) relative to the WT. (f) Macroscopic images of harvested fetal livers demonstrate marked hypoplasia in the KO liver compared to the WT. (g-j) Quantitative analysis and flow cytometry data show a decrease in total fetal liver cellularity and absolute numbers of Ter119+ erythroid cells in KO embryos, indicating impaired definitive erythropoiesis. Collectively, the data demonstrate that Stk40 deficiency leads to fetal anemia, edema, and hepatic hematopoietic defects.

Reading File
Reading File
Finding Sources
Reading File
Loading Image
Finding Sources
Loading Image
Reading File
Finding Sources
Reading File
Loading Image
Reading File
Loading Image
I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.

Erythropoiesis

Erythropoiesis is the process by which red blood cells (erythrocytes) are continuously produced to maintain adequate oxygen delivery to tissues. It occurs primarily in the red bone marrow in adults.

1. Sites of Erythropoiesis

Life StagePrimary Site
Early embryo (up to 6 weeks)Yolk sac (primitive erythropoiesis)
Fetal life (6 weeks - birth)Liver, then spleen
AdultsRed bone marrow (vertebrae, ribs, sternum, pelvis, proximal long bones)
In severe hemolytic anemia, the liver and spleen can reactivate as sites - this is called extramedullary erythropoiesis.

2. Stages of Erythroid Development

The entire process from stem cell to reticulocyte release takes approximately 7 days.

Progenitor (Non-morphologically distinct) Stages

These cells cannot be identified by light microscopy alone:
Pluripotent Hematopoietic Stem Cell (HSC)
        ↓
Common Myeloid Progenitor (CMP / CFU-GEMM)
        ↓
BFU-EMeg (Burst-Forming Unit - Erythroid/Megakaryocyte)
        ↓
BFU-E (Burst-Forming Unit - Erythroid)   ← EPO acts here
        ↓
CFU-E (Colony-Forming Unit - Erythroid)  ← EPO acts here (strongly)
(Basic Medical Biochemistry - A Clinical Approach, p. 1536)

Morphologically Recognizable (Erythroblast) Stages

Each stage undergoes mitotic division, and with each division the cell gets smaller and the nucleus more condensed:
StageKey FeaturesDivision Capable?
Proerythroblast (Pronormoblast)Largest cell; large nucleus with nucleoli; basophilic cytoplasm; NO hemoglobinYes
Basophilic ErythroblastSmaller; nucleoli absent; deeply basophilic cytoplasm from ribosomes; Hb synthesis beginsYes
Polychromatophilic ErythroblastHb accumulates; cytoplasm stains blue-gray (mixed basophilia + eosinophilia); nucleus smaller & condensedYes (last stage to divide)
Orthochromatic Erythroblast (Normoblast)Nucleus very small & densely pyknotic; cytoplasm predominantly eosinophilic (pink); near mature RBC sizeNo
ReticulocyteNucleus extruded; residual ribosomes + mRNA present (still synthesizes Hb); slight basophilia; released into circulationNo
Mature ErythrocyteBiconcave disc; no nucleus, no organelles; pure eosinophilicNo
(Histology - A Text and Atlas, p. 777; Guyton & Hall Medical Physiology, p. 442)
Below is the erythropoietin stimulation pathway from stem cell to circulating RBC:
EPO stimulation of erythrocyte maturation - from stem cells through CFU-GEMM, BFU-E, CFU-E, pronormoblast, reticulocyte to circulating red cells, regulated by kidney O2 sensor

3. Key Cellular Changes During Maturation

  • Cell size: progressively decreases
  • Nucleus: progressively smaller, chromatin condenses, ultimately extruded at normoblast stage
  • Cytoplasm: shifts from basophilic (ribosomes) → polychromatic → eosinophilic (hemoglobin)
  • Hemoglobin synthesis: begins at the basophilic erythroblast stage, peaks at polychromatophilic stage
  • Nuclear-to-cytoplasmic ratio: decreases with each division

4. Regulation by Erythropoietin (EPO)

Erythropoietin feedback loop - decreased tissue oxygenation stimulates kidney to produce EPO which drives proerythroblast formation and RBC production
Trigger: Decreased tissue oxygen delivery (hypoxia) stimulates EPO production.
Molecular mechanism:
  • Hypoxia stabilizes the transcription factor HIF-1α (hypoxia-inducible factor-1α)
  • HIF-1α binds to the hypoxia response element (HRE) in the EPO gene promoter
  • This drives transcription and synthesis of EPO
Source of EPO:
  • ~90% from the kidneys (fibroblast-like interstitial cells in the renal cortex/outer medulla surrounding peritubular capillaries)
  • ~10% from the liver
Actions of EPO:
  1. Stimulates CFU-E and BFU-E progenitors to proliferate
  2. Drives proerythroblast formation from hematopoietic stem cells
  3. Accelerates maturation through the erythroblast stages
  4. Prevents apoptosis of erythroid precursors
Clinical implication: When both kidneys are removed or destroyed by renal disease, only ~1/3 to 1/2 of normal RBC production can be maintained by hepatic EPO alone - causing anemia of chronic kidney disease (CKD).
(Guyton & Hall Medical Physiology, pp. 443-444)
Factors that decrease tissue oxygenation and thus stimulate EPO production:
  • Low blood volume
  • Anemia
  • Low hemoglobin
  • Poor blood flow
  • Pulmonary disease
  • High altitude

5. The Reticulocyte

  • The reticulocyte is the polychromatophilic erythrocyte - a red cell that has just extruded its nucleus
  • It still contains ribosomes, remnants of Golgi, and mitochondria
  • With special stains (e.g., new methylene blue), residual ribosomes clump to form a visible reticular network - hence the name
  • Reticulocytes circulate for 1-2 days, then mature in the spleen where ribosomes/mRNA are lost
  • Normal reticulocyte count: <1% of circulating RBCs
  • Elevated reticulocyte count = sign of active bone marrow erythropoiesis (e.g., hemolytic anemia, hemorrhage)
(Histology - A Text and Atlas, p. 778)

6. RBC Lifespan and Destruction

  • Mature erythrocytes live approximately 120 days
  • Senescent RBCs are phagocytosed by macrophages in the spleen, bone marrow, and liver (the mononuclear phagocyte system)
  • Heme is broken down: iron is recycled to the storage pool (ferritin/hemosiderin), the porphyrin ring is degraded to bilirubin → conjugated in the liver → excreted in bile
  • Globin chains are hydrolyzed to amino acids and recycled

7. Nutritional Requirements for Erythropoiesis

NutrientRole
Iron (Fe²⁺)Essential for heme synthesis; deficiency causes microcytic hypochromic anemia
Vitamin B12Required for DNA synthesis (thymidine synthesis); deficiency causes megaloblastic anemia
Folate (B9)Required for DNA synthesis; deficiency causes megaloblastic anemia
Vitamin B6Co-factor in heme synthesis
CopperRequired for iron mobilization
Vitamin CEnhances iron absorption
ErythropoietinHormonal driver (see above)

8. Quick Summary Diagram

HSC → CFU-GEMM → BFU-E → CFU-E
                              ↓ (EPO acts strongly here)
                     Proerythroblast (pronormoblast)
                              ↓ (4 mitotic divisions)
                     Basophilic erythroblast
                              ↓ (Hb synthesis begins)
                     Polychromatophilic erythroblast
                              ↓ (last mitosis)
                     Orthochromatic erythroblast (normoblast)
                              ↓ (nucleus extruded)
                     Reticulocyte → released into blood
                              ↓ (1-2 days in circulation)
                     Mature erythrocyte (RBC)
                              ↓ (120 days lifespan)
                     Destruction by macrophages → iron recycled
Sources: Guyton & Hall Textbook of Medical Physiology; Histology: A Text and Atlas (Pawlina & Ross); Basic Medical Biochemistry - A Clinical Approach, 6e

Anemia

Reading File
Finding Sources
Finding Sources
Searching Images

anemia classification microcytic normocytic macrocytic blood smear peripheral

This peripheral blood smear was prepared and stained with Wright-Giemsa and examined by bright-field light microscopy to assess circulating hematopoietic cells in suspected systemic mastocytosis (SM). The smear shows rare, but conspicuous, mast cells with round to polygonal shapes and abundant cytoplasmic granules that impart a deep purple, metachromatic appearance. Nuclei are generally round to ovoid and may be slightly irregular or bilobed in some cells; granules occupy most of the cytoplasm and may obscure nuclear detail. The surrounding leukocytes include eosinophils and neutrophils, and the erythrocyte background is normocytic with occasional anisocytosis. In SM, circulating mast cells are typically infrequent; when they constitute a substantial fraction of leukocytes (≥10%), the finding is highly suggestive of mast cell leukemia (MCL). The image exemplifies an increased mast cell burden consistent with aggressive SM or MCL, often accompanied by cytopenias such as anemia or thrombocytopenia and potential associated hematologic neoplasms (e.g., CMML, MDS/MPN). This morphologic snapshot supports integration with phenotypic assays (CD117/c-KIT), flow cytometry, and molecular testing for KIT mutations, to establish diagnosis, prognostication, and therapeutic planning. Relevant keywords: systemic mastocytosis, mast cell leukemia, circulating mast cells, metachromatic granules, Wright-Giemsa, toluidine blue, KIT D816V, CD117, SM-AHN. This description emphasizes morphology guiding diagnosis appropriately.

This peripheral blood smear was prepared and stained with Wright-Giemsa and examined by bright-field light microscopy to assess circulating hematopoietic cells in suspected systemic mastocytosis (SM). The smear shows rare, but conspicuous, mast cells with round to polygonal shapes and abundant cytoplasmic granules that impart a deep purple, metachromatic appearance. Nuclei are generally round to ovoid and may be slightly irregular or bilobed in some cells; granules occupy most of the cytoplasm and may obscure nuclear detail. The surrounding leukocytes include eosinophils and neutrophils, and the erythrocyte background is normocytic with occasional anisocytosis. In SM, circulating mast cells are typically infrequent; when they constitute a substantial fraction of leukocytes (≥10%), the finding is highly suggestive of mast cell leukemia (MCL). The image exemplifies an increased mast cell burden consistent with aggressive SM or MCL, often accompanied by cytopenias such as anemia or thrombocytopenia and potential associated hematologic neoplasms (e.g., CMML, MDS/MPN). This morphologic snapshot supports integration with phenotypic assays (CD117/c-KIT), flow cytometry, and molecular testing for KIT mutations, to establish diagnosis, prognostication, and therapeutic planning. Relevant keywords: systemic mastocytosis, mast cell leukemia, circulating mast cells, metachromatic granules, Wright-Giemsa, toluidine blue, KIT D816V, CD117, SM-AHN. This description emphasizes morphology guiding diagnosis appropriately.

This image depicts a peripheral blood smear prepared with Wright-Giemsa stain and examined under light microscopy at high magnification. The predominant features are small, mature-appearing lymphocytes with scant cytoplasm and discrete basophilic nuclei interspersed among erythrocytes. A characteristic subset of circulating lymphocytes displays short, polarity-restricted cytoplasmic villi (finger-like projections) consistent with splenic marginal zone lymphoma (SMZL) involvement of peripheral blood. The villi are typically slender and localized to one pole of the cell, unlike the longer, circumferential villous extensions seen in hairy cell leukemia, which aids in differential diagnosis. Some lymphocytes appear slightly irregular or irregular nuclear contours; occasional larger atypical cells may be present but are less common. The background shows normocytic red cells with normal distribution; platelets are not prominent. This cytomorphology supports SMZL in the context of known splenomegaly or lymphoproliferative disease and is often corroborated by immunophenotyping and molecular studies. Clinically, peripheral blood involvement occurs in roughly half to two-thirds of SMZL cases and helps establish disease burden. The image illustrates the diagnostic utility of meticulous peripheral smear review for small-vessel lymphocytosis and villous lymphocytes, informing differential diagnoses, guiding flow cytometry panels, and contributing to monitoring and prognosis.

This image depicts a peripheral blood smear prepared with Wright-Giemsa stain and examined under light microscopy at high magnification. The predominant features are small, mature-appearing lymphocytes with scant cytoplasm and discrete basophilic nuclei interspersed among erythrocytes. A characteristic subset of circulating lymphocytes displays short, polarity-restricted cytoplasmic villi (finger-like projections) consistent with splenic marginal zone lymphoma (SMZL) involvement of peripheral blood. The villi are typically slender and localized to one pole of the cell, unlike the longer, circumferential villous extensions seen in hairy cell leukemia, which aids in differential diagnosis. Some lymphocytes appear slightly irregular or irregular nuclear contours; occasional larger atypical cells may be present but are less common. The background shows normocytic red cells with normal distribution; platelets are not prominent. This cytomorphology supports SMZL in the context of known splenomegaly or lymphoproliferative disease and is often corroborated by immunophenotyping and molecular studies. Clinically, peripheral blood involvement occurs in roughly half to two-thirds of SMZL cases and helps establish disease burden. The image illustrates the diagnostic utility of meticulous peripheral smear review for small-vessel lymphocytosis and villous lymphocytes, informing differential diagnoses, guiding flow cytometry panels, and contributing to monitoring and prognosis.

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

This composite image consists of clinical photographs and a diagnostic peripheral blood smear. Figure 1a (left) shows a pediatric patient with clinical signs including total alopecia (complete absence of scalp hair) and nail pitting affecting both hands and feet, characterized by small punctate depressions on the nail plates. Figure 1b (right) is a microscopic view of a peripheral blood smear demonstrating microangiopathic hemolytic anemia. Visible are numerous schistocytes—fragmented, irregular red blood cells including helmet cells and triangular forms—alongside some normal erythrocytes showing central pallor. The educational focus is on the multi-systemic manifestations of a medical condition, likely a microangiopathic process such as Hemolytic Uremic Syndrome (HUS) or similar systemic pathology, illustrating the correlation between dermatological signs (hair and nail changes) and hematological abnormalities (hemolysis and schistocytosis).

This composite image consists of clinical photographs and a diagnostic peripheral blood smear. Figure 1a (left) shows a pediatric patient with clinical signs including total alopecia (complete absence of scalp hair) and nail pitting affecting both hands and feet, characterized by small punctate depressions on the nail plates. Figure 1b (right) is a microscopic view of a peripheral blood smear demonstrating microangiopathic hemolytic anemia. Visible are numerous schistocytes—fragmented, irregular red blood cells including helmet cells and triangular forms—alongside some normal erythrocytes showing central pallor. The educational focus is on the multi-systemic manifestations of a medical condition, likely a microangiopathic process such as Hemolytic Uremic Syndrome (HUS) or similar systemic pathology, illustrating the correlation between dermatological signs (hair and nail changes) and hematological abnormalities (hemolysis and schistocytosis).

Comprehensive description: Brightfield light microscopy image of a peripheral blood smear stained with Wright-Giemsa, captured at high magnification to visualize circulating plasma cells. The central plasmablast shows an enlarged, irregular nucleus with a prominent nucleolus; the cytoplasm is moderately basophilic. This cell appears larger than surrounding erythrocytes and is consistent with malignant plasma cells typical of plasma cell leukemia. The background demonstrates rouleaux formation of red blood cells, a common feature in paraproteinemias due to increased serum proteins. The smear illustrates plasmacytosis that, when exceeding 20% of leukocytes, supports a diagnosis of plasma cell leukemia. In PCL, neoplastic plasma cells may be CD56 negative and often secrete monoclonal immunoglobulin with IgD or IgE isotypes or light-chain restriction; cytogenetic abnormalities are frequently observed. Morphology alone cannot definitively distinguish PCL from aggressive myeloma; immunophenotyping and cytogenetic studies are essential for precise classification. This image is valuable for hematology education, cytology review, and discussions of malignant plasma cell disorders, including primary versus secondary PCL, and their prognostic significance. Potential clinical utilities include morphologic confirmation in suspected PCL, training in recognition of plasmablasts, and correlation with CBC abnormalities and clinical features such as anemia, thrombocytopenia, lymphadenopathy, and organomegaly.

Comprehensive description: Brightfield light microscopy image of a peripheral blood smear stained with Wright-Giemsa, captured at high magnification to visualize circulating plasma cells. The central plasmablast shows an enlarged, irregular nucleus with a prominent nucleolus; the cytoplasm is moderately basophilic. This cell appears larger than surrounding erythrocytes and is consistent with malignant plasma cells typical of plasma cell leukemia. The background demonstrates rouleaux formation of red blood cells, a common feature in paraproteinemias due to increased serum proteins. The smear illustrates plasmacytosis that, when exceeding 20% of leukocytes, supports a diagnosis of plasma cell leukemia. In PCL, neoplastic plasma cells may be CD56 negative and often secrete monoclonal immunoglobulin with IgD or IgE isotypes or light-chain restriction; cytogenetic abnormalities are frequently observed. Morphology alone cannot definitively distinguish PCL from aggressive myeloma; immunophenotyping and cytogenetic studies are essential for precise classification. This image is valuable for hematology education, cytology review, and discussions of malignant plasma cell disorders, including primary versus secondary PCL, and their prognostic significance. Potential clinical utilities include morphologic confirmation in suspected PCL, training in recognition of plasmablasts, and correlation with CBC abnormalities and clinical features such as anemia, thrombocytopenia, lymphadenopathy, and organomegaly.

Imaging modality and technique: Light microscopy on peripheral blood smear stained with Wright-Giemsa. Specimen type: peripheral blood smear. Primary subject: Hairy cells. Anatomical context: hematopoietic peripheral blood. Observed morphology: Hairy cells are larger than small lymphocytes, about 1.5–2× the size; nuclei are oval to bean-shaped with open, coarse chromatin and inconspicuous nucleoli. Cytoplasm is moderate in volume, pale blue, with fine, hair-like cytoplasmic projections that extend from the cell surface. Chromatin is evenly dispersed; nucleoli are not prominent. The smear shows scattered hairy cells among a background of normocytic erythrocytes and neutrophils. In some cases cytoplasm may appear flocculent; proplate-like projections are best seen in well-prepared thin areas of smear. This morphology is best appreciated on peripheral smear preparations rather than aspirate smears, where hair projections may be less evident. Diagnostic significance: characteristic hairy cell features suggest a diagnosis of hairy cell leukemia (HCL) in appropriate clinical context; TRAP positivity, CD11c, CD25, and CD103 expression support the diagnosis. Clinical correlation includes cytopenias, splenomegaly, and exposure to risk factors; differential includes other lymphoid and myeloid disorders with cytoplasmic projections or atypical lymphocytes. Utility in education and differential diagnosis: hematology teaching, smear interpretation, cellular morphologic recognition, and confirmation with flow cytometry.

Imaging modality and technique: Light microscopy on peripheral blood smear stained with Wright-Giemsa. Specimen type: peripheral blood smear. Primary subject: Hairy cells. Anatomical context: hematopoietic peripheral blood. Observed morphology: Hairy cells are larger than small lymphocytes, about 1.5–2× the size; nuclei are oval to bean-shaped with open, coarse chromatin and inconspicuous nucleoli. Cytoplasm is moderate in volume, pale blue, with fine, hair-like cytoplasmic projections that extend from the cell surface. Chromatin is evenly dispersed; nucleoli are not prominent. The smear shows scattered hairy cells among a background of normocytic erythrocytes and neutrophils. In some cases cytoplasm may appear flocculent; proplate-like projections are best seen in well-prepared thin areas of smear. This morphology is best appreciated on peripheral smear preparations rather than aspirate smears, where hair projections may be less evident. Diagnostic significance: characteristic hairy cell features suggest a diagnosis of hairy cell leukemia (HCL) in appropriate clinical context; TRAP positivity, CD11c, CD25, and CD103 expression support the diagnosis. Clinical correlation includes cytopenias, splenomegaly, and exposure to risk factors; differential includes other lymphoid and myeloid disorders with cytoplasmic projections or atypical lymphocytes. Utility in education and differential diagnosis: hematology teaching, smear interpretation, cellular morphologic recognition, and confirmation with flow cytometry.

Reading File
Reading File
Searching Images

iron deficiency anemia microcytic hypochromic blood smear RBC pencil cells

Educational figure illustrating hematological abnormalities in a murine model of Prkab1 deficiency, serving as a surrogate for studying human hemolytic anemia and microcytosis. Panels A-F present dot plots of hematological indices for wild-type (Prkab1+/+) and deficient (Prkab1tm1b/tm1b) mice, showing significant reductions in hemoglobin (A), hematocrit (B), and mean corpuscular volume (E), with a concomitant increase in red blood cell distribution width (F), indicating microcytic anemia with anisocytosis. Panel G contains high-resolution Scanning Electron Microscopy (SEM) images comparing erythrocyte morphology; wild-type cells show standard biconcave discocyte morphology, whereas Prkab1-deficient cells exhibit poikilocytosis with numerous abnormal forms, including acanthocytes, schistocytes, and echinocytes with irregular surface protrusions. Panel H displays an osmotic resistance curve, where Prkab1-deficient erythrocytes demonstrate a left-ward shift, signifying increased osmotic resistance (delayed hemolysis) compared to wild-type controls. The inset confirms a lower NaCl percentage required for 50% hemolysis in deficient cells, indicating altered membrane stability.

Educational figure illustrating hematological abnormalities in a murine model of Prkab1 deficiency, serving as a surrogate for studying human hemolytic anemia and microcytosis. Panels A-F present dot plots of hematological indices for wild-type (Prkab1+/+) and deficient (Prkab1tm1b/tm1b) mice, showing significant reductions in hemoglobin (A), hematocrit (B), and mean corpuscular volume (E), with a concomitant increase in red blood cell distribution width (F), indicating microcytic anemia with anisocytosis. Panel G contains high-resolution Scanning Electron Microscopy (SEM) images comparing erythrocyte morphology; wild-type cells show standard biconcave discocyte morphology, whereas Prkab1-deficient cells exhibit poikilocytosis with numerous abnormal forms, including acanthocytes, schistocytes, and echinocytes with irregular surface protrusions. Panel H displays an osmotic resistance curve, where Prkab1-deficient erythrocytes demonstrate a left-ward shift, signifying increased osmotic resistance (delayed hemolysis) compared to wild-type controls. The inset confirms a lower NaCl percentage required for 50% hemolysis in deficient cells, indicating altered membrane stability.

Educational medical image panel consisting of a clinical photograph and a diagnostic pathology image illustrating physical and hematological findings of a hemoglobinopathy such as Hb E/beta-thalassemia. Panel A is a clinical photograph of a patient's abdomen showing a prominent bulge in the left upper quadrant and mid-abdomen, with a black arrow indicating the anterior notch of a massively enlarged spleen (splenomegaly). The overlying skin shows subtle striae or discoloration. Panel B is a peripheral blood smear (Leishman stain, 200x) showing significant red blood cell (RBC) dysmorphology. Key findings include target cells (codocytes) marked by black arrows, teardrop cells (dacrocytes) marked by blue arrows, and basophilic stippling within microcytic, hypochromic RBCs marked by yellow arrows. These visual markers are classic indicators of disordered erythropoiesis and hemoglobin synthesis abnormalities, providing a diagnostic bridge between clinical examination (splenomegaly) and laboratory hematopathology.

Educational medical image panel consisting of a clinical photograph and a diagnostic pathology image illustrating physical and hematological findings of a hemoglobinopathy such as Hb E/beta-thalassemia. Panel A is a clinical photograph of a patient's abdomen showing a prominent bulge in the left upper quadrant and mid-abdomen, with a black arrow indicating the anterior notch of a massively enlarged spleen (splenomegaly). The overlying skin shows subtle striae or discoloration. Panel B is a peripheral blood smear (Leishman stain, 200x) showing significant red blood cell (RBC) dysmorphology. Key findings include target cells (codocytes) marked by black arrows, teardrop cells (dacrocytes) marked by blue arrows, and basophilic stippling within microcytic, hypochromic RBCs marked by yellow arrows. These visual markers are classic indicators of disordered erythropoiesis and hemoglobin synthesis abnormalities, providing a diagnostic bridge between clinical examination (splenomegaly) and laboratory hematopathology.

A comparative medical illustration detailing the effects of iron dysregulation on wound healing and systemic states. The left panel depicts a 'Low Iron' and 'Inflammation' scenario where a cutaneous wound is associated with 'Iron-deficiency anemia'. Key signaling molecules shown include TGF, IL-6, IL-8, and ECM components within a wound bed containing fibroblasts and matrix elements. An arrow indicates the downstream impact on the underlying epithelium and hemoglobin within the bloodstream. The right panel depicts an 'Excessive Iron' and 'Skin damage' scenario characterized by 'Excessive iron deposition'. This state is visually distinguished by an inhibitory symbol (red T-bar) directed at the epithelium, suggesting impaired regenerative capacity. Notably, the epithelium in the high-iron state contains yellow granules labeled as 'Iron-containing haematoxylin' (hemosiderin), which serve as a histological marker of iron overload. Both panels show the anatomical relationship between the cutaneous wound, underlying epithelial cells, and the intravascular space (bloodstream) containing red blood cells and hemoglobin, illustrating how iron homeostasis is critical for normal dermatological repair and systemic oxygen transport.

A comparative medical illustration detailing the effects of iron dysregulation on wound healing and systemic states. The left panel depicts a 'Low Iron' and 'Inflammation' scenario where a cutaneous wound is associated with 'Iron-deficiency anemia'. Key signaling molecules shown include TGF, IL-6, IL-8, and ECM components within a wound bed containing fibroblasts and matrix elements. An arrow indicates the downstream impact on the underlying epithelium and hemoglobin within the bloodstream. The right panel depicts an 'Excessive Iron' and 'Skin damage' scenario characterized by 'Excessive iron deposition'. This state is visually distinguished by an inhibitory symbol (red T-bar) directed at the epithelium, suggesting impaired regenerative capacity. Notably, the epithelium in the high-iron state contains yellow granules labeled as 'Iron-containing haematoxylin' (hemosiderin), which serve as a histological marker of iron overload. Both panels show the anatomical relationship between the cutaneous wound, underlying epithelial cells, and the intravascular space (bloodstream) containing red blood cells and hemoglobin, illustrating how iron homeostasis is critical for normal dermatological repair and systemic oxygen transport.

This composite educational image illustrates the multisystem clinical and pathological manifestations of Fanconi Anemia (FA), highlighting the impact of FA/BRCA pathway deficits. (A) Histological micrograph of bone marrow showing hypocellularity and attrition of hematopoietic progenitors, indicative of bone marrow failure. (B) High-power microscopy of a blood smear or marrow showing blast cells with chromosomal aberrations, representing acute myeloblastic leukemia (AML). (C) Clinical photograph demonstrating somatometric features, specifically short stature and microcephaly. (D) Clinical photographs of skin showing pigmentary abnormalities, including hyperpigmented café au lait macules (left) and hypopigmented (hypochromic) macules (right). (E) A series of clinical photographs depicting the 'Thumb Phenotype Spectrum,' ranging from hyperplasia (top) to normal, and descending into degrees of hypoplasia and aplasia (bottom), with labels for left and right hand laterality. The bottom panel provides a conceptual framework linking these features to the loss of pluripotent cells, acquired chromosomal alterations, and stochastic events within the FA/BRCA and related developmental pathways.

This composite educational image illustrates the multisystem clinical and pathological manifestations of Fanconi Anemia (FA), highlighting the impact of FA/BRCA pathway deficits. (A) Histological micrograph of bone marrow showing hypocellularity and attrition of hematopoietic progenitors, indicative of bone marrow failure. (B) High-power microscopy of a blood smear or marrow showing blast cells with chromosomal aberrations, representing acute myeloblastic leukemia (AML). (C) Clinical photograph demonstrating somatometric features, specifically short stature and microcephaly. (D) Clinical photographs of skin showing pigmentary abnormalities, including hyperpigmented café au lait macules (left) and hypopigmented (hypochromic) macules (right). (E) A series of clinical photographs depicting the 'Thumb Phenotype Spectrum,' ranging from hyperplasia (top) to normal, and descending into degrees of hypoplasia and aplasia (bottom), with labels for left and right hand laterality. The bottom panel provides a conceptual framework linking these features to the loss of pluripotent cells, acquired chromosomal alterations, and stochastic events within the FA/BRCA and related developmental pathways.

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

This composite educational graphic illustrates hematopoietic abnormalities in MommeD7 mutant mice across multiple modalities. Panel (a) contains clinical photographs of 17.5 dpc embryos, comparing a phenotypically normal (red/vascularized) embryo with an abnormal, pale embryo suggestive of severe anemia or a red cell defect. Panel (b) is a bar graph showing significant splenomegaly in adult heterozygous (-/+) mice compared to wild-type (+/+). Panel (c) presents light microscopy of peripheral blood smears; the mutant smear (-/+) displays a high frequency of reticulocytes—identified by characteristic punctate blue staining (arrowheads)—indicating a compensatory response to anemia. Panel (d) shows flow cytometry histograms of propidium iodide fluorescence, quantifying the shift from mature red blood cells (RBC) to an increased reticulocyte (RET) population in the mutant. Panel (e) uses a bar chart to compare average mean GFP fluorescence, demonstrating higher expression levels in reticulocytes versus RBCs, particularly in the heterozygous line. Collectively, these images illustrate the pathophysiology of a hematopoietic mutation leading to embryonic pallor, adult splenomegaly, and increased reticulocytosis.

This composite educational graphic illustrates hematopoietic abnormalities in MommeD7 mutant mice across multiple modalities. Panel (a) contains clinical photographs of 17.5 dpc embryos, comparing a phenotypically normal (red/vascularized) embryo with an abnormal, pale embryo suggestive of severe anemia or a red cell defect. Panel (b) is a bar graph showing significant splenomegaly in adult heterozygous (-/+) mice compared to wild-type (+/+). Panel (c) presents light microscopy of peripheral blood smears; the mutant smear (-/+) displays a high frequency of reticulocytes—identified by characteristic punctate blue staining (arrowheads)—indicating a compensatory response to anemia. Panel (d) shows flow cytometry histograms of propidium iodide fluorescence, quantifying the shift from mature red blood cells (RBC) to an increased reticulocyte (RET) population in the mutant. Panel (e) uses a bar chart to compare average mean GFP fluorescence, demonstrating higher expression levels in reticulocytes versus RBCs, particularly in the heterozygous line. Collectively, these images illustrate the pathophysiology of a hematopoietic mutation leading to embryonic pallor, adult splenomegaly, and increased reticulocytosis.

Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Searching Images

sickle cell anemia peripheral blood smear sickle cells target cells

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

Peripheral blood smear prepared with Wright-Giemsa stain and examined under brightfield illumination using a 100× oil immersion objective reveals a single large plasma cell among a field of mature erythrocytes. The plasma cell displays features typical of clonal plasma cells: basophilic cytoplasm, an eccentrically placed round nucleus, and a conspicuous perinuclear hof; background shows rouleaux formation of red cells. This image exemplifies hematologic involvement by a plasma cell dyscrasia. In plasma cell leukemia, circulating plasma cells constitute more than 20% of leukocytes, a hallmark distinguishing it from conventional multiple myeloma, although both conditions share monoclonal plasma cell proliferation. The presence of circulating plasma cells is associated with younger patient age, higher incidence of anemia, thrombocytopenia, organomegaly, and possible lymphadenopathy; however lytic bone lesions may be less common. Immunophenotypic patterns often include lack of CD56 expression relative to myeloma. Clinically, this morphological finding warrants confirmation with complete blood count, peripheral smear review, quantitative plasma cell percentage, serum protein electrophoresis, and immunofixation to identify monoclonal immunoglobulin isotype (IgD/IgE or light-chain predominance). Early detection of circulating plasma cells supports prognosis assessment and guides therapy decisions in plasma cell dyscrasia management and monitoring, including risk stratification and treatment response evaluation for practice in clinics.

Peripheral blood smear prepared with Wright-Giemsa stain and examined under brightfield illumination using a 100× oil immersion objective reveals a single large plasma cell among a field of mature erythrocytes. The plasma cell displays features typical of clonal plasma cells: basophilic cytoplasm, an eccentrically placed round nucleus, and a conspicuous perinuclear hof; background shows rouleaux formation of red cells. This image exemplifies hematologic involvement by a plasma cell dyscrasia. In plasma cell leukemia, circulating plasma cells constitute more than 20% of leukocytes, a hallmark distinguishing it from conventional multiple myeloma, although both conditions share monoclonal plasma cell proliferation. The presence of circulating plasma cells is associated with younger patient age, higher incidence of anemia, thrombocytopenia, organomegaly, and possible lymphadenopathy; however lytic bone lesions may be less common. Immunophenotypic patterns often include lack of CD56 expression relative to myeloma. Clinically, this morphological finding warrants confirmation with complete blood count, peripheral smear review, quantitative plasma cell percentage, serum protein electrophoresis, and immunofixation to identify monoclonal immunoglobulin isotype (IgD/IgE or light-chain predominance). Early detection of circulating plasma cells supports prognosis assessment and guides therapy decisions in plasma cell dyscrasia management and monitoring, including risk stratification and treatment response evaluation for practice in clinics.

This peripheral blood smear was prepared and stained with Wright-Giemsa and examined by bright-field light microscopy to assess circulating hematopoietic cells in suspected systemic mastocytosis (SM). The smear shows rare, but conspicuous, mast cells with round to polygonal shapes and abundant cytoplasmic granules that impart a deep purple, metachromatic appearance. Nuclei are generally round to ovoid and may be slightly irregular or bilobed in some cells; granules occupy most of the cytoplasm and may obscure nuclear detail. The surrounding leukocytes include eosinophils and neutrophils, and the erythrocyte background is normocytic with occasional anisocytosis. In SM, circulating mast cells are typically infrequent; when they constitute a substantial fraction of leukocytes (≥10%), the finding is highly suggestive of mast cell leukemia (MCL). The image exemplifies an increased mast cell burden consistent with aggressive SM or MCL, often accompanied by cytopenias such as anemia or thrombocytopenia and potential associated hematologic neoplasms (e.g., CMML, MDS/MPN). This morphologic snapshot supports integration with phenotypic assays (CD117/c-KIT), flow cytometry, and molecular testing for KIT mutations, to establish diagnosis, prognostication, and therapeutic planning. Relevant keywords: systemic mastocytosis, mast cell leukemia, circulating mast cells, metachromatic granules, Wright-Giemsa, toluidine blue, KIT D816V, CD117, SM-AHN. This description emphasizes morphology guiding diagnosis appropriately.

This peripheral blood smear was prepared and stained with Wright-Giemsa and examined by bright-field light microscopy to assess circulating hematopoietic cells in suspected systemic mastocytosis (SM). The smear shows rare, but conspicuous, mast cells with round to polygonal shapes and abundant cytoplasmic granules that impart a deep purple, metachromatic appearance. Nuclei are generally round to ovoid and may be slightly irregular or bilobed in some cells; granules occupy most of the cytoplasm and may obscure nuclear detail. The surrounding leukocytes include eosinophils and neutrophils, and the erythrocyte background is normocytic with occasional anisocytosis. In SM, circulating mast cells are typically infrequent; when they constitute a substantial fraction of leukocytes (≥10%), the finding is highly suggestive of mast cell leukemia (MCL). The image exemplifies an increased mast cell burden consistent with aggressive SM or MCL, often accompanied by cytopenias such as anemia or thrombocytopenia and potential associated hematologic neoplasms (e.g., CMML, MDS/MPN). This morphologic snapshot supports integration with phenotypic assays (CD117/c-KIT), flow cytometry, and molecular testing for KIT mutations, to establish diagnosis, prognostication, and therapeutic planning. Relevant keywords: systemic mastocytosis, mast cell leukemia, circulating mast cells, metachromatic granules, Wright-Giemsa, toluidine blue, KIT D816V, CD117, SM-AHN. This description emphasizes morphology guiding diagnosis appropriately.

Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Loading Image
Reading File
Loading Image
Loading Image
I now have rich, comprehensive content from multiple authoritative textbooks. Let me compile the full answer.

Anemia - Comprehensive Overview


1. Definition

Anemia is defined as blood counts below normal for a given population - specifically a reduction in hemoglobin concentration, hematocrit, or RBC count. It is not a diagnosis in itself but a sign of an underlying process.
Normal Reference Ranges (Adults) - Robbins Pathologic Basis of Disease:
MeasurementMalesFemales
Hemoglobin (g/dL)13.6 - 17.212.0 - 15.0
Hematocrit (%)39 - 4933 - 43
RBC count (×10⁶/µL)4.3 - 5.93.5 - 5.0
MCV (fL)82 - 96
MCH (pg)27 - 33
MCHC (g/dL)33 - 37
Reticulocyte count (%)0.5 - 1.5
WHO definitions: Hb < 13 g/dL (men), < 12 g/dL (women), < 11 g/dL (pregnant women).

2. Pathophysiologic Classification

(Robbins, Cotran & Kumar - Pathologic Basis of Disease)

A. Blood Loss

  • Acute: Trauma, surgery - initially normocytic/normochromic; reticulocytosis at 7 days (up to 10-15%)
  • Chronic: GI lesions, gynecologic causes - eventually leads to iron deficiency anemia

B. Increased RBC Destruction (Hemolytic Anemias)

Inherited:
  • RBC membrane defects: Hereditary spherocytosis, hereditary elliptocytosis
  • Enzyme deficiencies: G6PD deficiency, pyruvate kinase deficiency
  • Hemoglobin abnormalities: Thalassemia syndromes, sickle cell disease
Acquired:
  • Antibody-mediated: Autoimmune hemolytic anemia, hemolytic disease of the newborn, transfusion reactions
  • Microangiopathic: HUS, DIC, TTP
  • Infections: Malaria, babesiosis
  • PNH (paroxysmal nocturnal hemoglobinuria)

C. Decreased RBC Production

  • Nutritional deficiencies: Iron, B12, folate
  • EPO deficiency: Anemia of chronic kidney disease
  • Bone marrow failure: Aplastic anemia, infiltration by malignancy
  • Chronic inflammation: Anemia of chronic disease
  • Primary hematopoietic neoplasms: Leukemia, MDS

3. Morphologic Classification by MCV

The MCV-based scheme, pioneered by Max Wintrobe, is the most practical diagnostic starting point:
Anemia classification by MCV - microcytic causes include iron deficiency, thalassemia, sideroblastic, lead poisoning
Peripheral blood smear comparing microcytic hypochromic RBCs (top) vs macrocytic RBCs (bottom), with lymphocyte nucleus as size reference
(From Frameworks for Internal Medicine / Wintrobe's Atlas of Clinical Hematology)

Microcytic Anemia (MCV < 80 fL)

Caused by anything that impairs hemoglobin production - less Hb means smaller cells.
CauseKey Feature
Iron deficiency anemiaMost common worldwide; low ferritin; high TIBC
ThalassemiaDefect in globin chain synthesis; target cells on smear
Anemia of chronic diseaseOften normocytic; hepcidin-mediated iron trapping
Sideroblastic anemiaRing sideroblasts on bone marrow; iron overload
Lead poisoningBasophilic stippling; elevated ZPP

Macrocytic Anemia (MCV > 100 fL)

Caused by defective DNA synthesis (oval macrocytes) or membrane/other defects (round macrocytes):
Oval Macrocytes (Megaloblastic)Round Macrocytes (Non-megaloblastic)
Vitamin B12 deficiencyLiver disease
Folate deficiencyAlcoholism
Medications (methotrexate, hydroxyurea)Hypothyroidism
MyelodysplasiaReticulocytosis

Normocytic Anemia (MCV 80-100 fL)

Broad differential - the reticulocyte count is the key to further narrowing:
CategoryExamples
Aplastic anemiaPancytopenia + bone marrow hypoplasia
Anemia of chronic/renal diseaseEPO deficiency
Acute blood lossEarly phase, before reticulocytosis
HemolysisWith reticulocytosis
Marrow infiltrationLeukemia, myeloma, myelofibrosis
EndocrinopathiesHypothyroidism, hypogonadism

4. Clinical Features

(Frameworks for Internal Medicine)
The clinical presentation depends on severity, chronicity, and rate of onset. Mild anemia is frequently asymptomatic.
Symptoms:
  • Fatigue and loss of stamina
  • Dyspnea on exertion
  • Headache, poor concentration
  • Palpitations
Physical Signs:
  • Pallor of skin, mucous membranes, conjunctiva, palmar creases, nail beds
  • Tachycardia
  • Wide pulse pressure, forceful heartbeat, strong peripheral pulses
  • Systolic flow murmur (hyperdynamic circulation)
Compensatory physiologic responses:
  • Increased cardiac output (increased stroke volume + heart rate)
  • Increased 2,3-BPG production (right-shifts oxygen-hemoglobin dissociation curve)
  • Decreased systemic vascular resistance
  • Increased coronary and cerebral blood flow
Condition-specific signs:
  • Jaundice + splenomegaly = hemolytic anemia
  • Koilonychia (spoon nails), glossitis, angular cheilitis = iron deficiency
  • Neurologic deficits (subacute combined degeneration) = B12 deficiency (NOT folate)
  • Bone pain + lytic lesions = myeloma

5. Diagnostic Approach

Step 1 - CBC + Reticulocyte Count
The absolute reticulocyte count is the single most important first step to determine mechanism:
Reticulocytes HIGH (>100,000/µL)  →  Increased destruction or blood loss
         (bone marrow responding)       (hemolysis, hemorrhage)

Reticulocytes LOW               →  Decreased production
         (bone marrow not responding)   (nutritional, aplasia, CKD)
Step 2 - MCV to narrow differential (see Section 3 above)
Step 3 - Targeted investigations
Suspected DiagnosisKey Tests
Iron deficiencySerum ferritin (most sensitive single test), serum iron, TIBC, transferrin saturation
B12/Folate deficiencySerum B12, RBC folate; hypersegmented neutrophils on smear
HemolysisLDH↑, indirect bilirubin↑, haptoglobin↓, peripheral smear (spherocytes, schistocytes)
Aplastic anemiaBone marrow biopsy (hypocellular marrow)
ThalassemiaHb electrophoresis, HPLC
Sickle cellHb electrophoresis (HbS)
Autoimmune hemolyticDirect Coombs (DAT) test

6. Key Individual Anemias

A. Iron Deficiency Anemia (IDA)

  • Most common cause of anemia worldwide
  • Causes: Malnutrition, chronic blood loss (GI most common in adults), malabsorption (celiac), increased demand (pregnancy)
  • Lab: Ferritin ↓ (earliest and most sensitive), serum iron ↓, TIBC ↑, transferrin saturation ↓
  • Smear: Microcytic, hypochromic cells; pencil/cigar cells (elongated hypochromic RBCs)
  • Treatment: Oral ferrous sulfate (3-6 months to replenish stores)

B. Megaloblastic Anemia (B12 / Folate Deficiency)

  • Macrocytic anemia with hypersegmented neutrophils (>5 lobes in >5% of cells) on smear
  • MCV typically >100 fL; pancytopenia in severe cases
  • B12 deficiency only causes neurologic symptoms: subacute combined degeneration (posterior + lateral column), paresthesias, ataxia, cognitive decline
  • Giving folate alone to an undiagnosed B12-deficient patient corrects anemia but worsens or unmasks neurologic damage - always rule out B12 deficiency first
  • Treatment: IM B12 (cyanocobalamin) or high-dose oral B12; folate supplementation

C. Hemolytic Anemias

  • Extravascular hemolysis: Anemia + splenomegaly + jaundice; haptoglobin low; LDH raised
  • Intravascular hemolysis: Anemia + hemoglobinemia + hemoglobinuria (red-brown urine) + hemosiderinuria; NO splenomegaly
  • Both: Elevated unconjugated (indirect) bilirubin, reticulocytosis, elevated LDH
G6PD deficiency: X-linked; episodic hemolysis triggered by infections, drugs (antimalarials, sulfonamides), fava beans; Heinz bodies; "bite cells" on smear
Sickle cell disease: HbS polymerizes under hypoxia; vaso-occlusion, splenic sequestration, acute chest syndrome; management: hydroxyurea, voxelotor, transfusion, stem cell transplant
Hereditary spherocytosis: Defect in spectrin/ankyrin; osmotic fragility test positive; responds well to splenectomy

D. Anemia of Chronic Disease (ACD)

  • Mild to moderate normocytic (sometimes microcytic) anemia
  • Mechanism: Hepcidin ↑ (from IL-6 in inflammation) → blocks ferroportin → serum iron ↓, TIBC ↓, ferritin normal or ↑ (distinguishes from IDA)
  • Associated with: Chronic infection, autoimmune disease, cancer, CKD
  • Treatment: Treat underlying cause; EPO agents in CKD

E. Aplastic Anemia

  • Bone marrow failure: pancytopenia (anemia + neutropenia + thrombocytopenia) with hypocellular bone marrow (>70% fat cells) in the absence of infiltrative disease
  • Causes: Idiopathic (most common), drugs, viruses (Parvovirus B19, hepatitis), radiation, autoimmune (T-cell mediated destruction of HSCs)
  • Treatment: Allogeneic bone marrow transplantation (young patients) or immunosuppression with anti-thymocyte globulin (ATG) + cyclosporine

7. Severity Grading

GradeHemoglobin (g/dL)
Mild10 - lower limit of normal
Moderate8 - 10
Severe6 - 8
Very severe / life-threatening< 6

8. Summary Diagnostic Algorithm

CBC shows low Hb/Hct
         ↓
Check Reticulocyte Count
    ↙                    ↘
HIGH (>100k)           LOW (<100k)
(Blood loss/Hemolysis)  (Underproduction)
    ↓                       ↓
Peripheral smear        Check MCV
LDH, bilirubin          ↙    ↓    ↘
Haptoglobin         Micro  Normo  Macro
Coombs test          ↓      ↓      ↓
                  Fe,TIBC  EPO,  B12/Folate
                  Hb elec  CKD,  Liver disease
                           BM bx  Thyroid
Sources: Harrison's Principles of Internal Medicine, 22e; Robbins, Cotran & Kumar Pathologic Basis of Disease; Frameworks for Internal Medicine; Guyton & Hall Medical Physiology
This is a shared conversation. Sign in to Orris to start your own chat.